Who We Work With

We serve biotech and pharma teams, investors, and deal-driven funds who need deep competitive and regulatory intelligence without building an in-house CI team.

Biotech Companies

Competitive intelligence for biotech teams, including pipeline monitoring, competitive landscape analysis, and regulatory intelligence for fundraising and strategic clinical development planning.

Pharma BD & CI Teams

Pharma competitor intelligence and competitive landscaping for commercial-stage pharma teams considering pipeline expansions, clinical timeline adjustments, and licensing / acquisition opportunities.

Biotech VCs & Accelerators

Indication and molecular deep dives including early entrant signals to de-risk thesis-driven investments, plus competitive positioning for portfolio companies approaching key milestones.

Life Sci PE & Growth Equity

Due diligence support for life-science portfolio acquisitions and add-ons; clinical, regulatory, and commercial intelligence delivered at deal speed.

How Biotech Teams Use Our Intelligence

Competitive Landscape Monitoring

Track key changes in competitor asset launch timelines, regulatory and clinical milestones, and new entrants to the development landscape.

Securing Future Funding

Access all relevant asset data for your target indication to build an airtight assessment of the commercial opportunity and secure investor funding.

Pipeline Development

Use signals from early-stage patent filings, pre-clinical developments, and more to identify new indications to expand into with your molecule.

Trial & Regulatory Strategy

Leverage insights from analogue and competitor trial protocols and regulatory engagements to strengthen your clinical and regulatory strategies.

How Pharma Teams Use Our Intelligence

BD&L Lead Sourcing

Use signals from globally sourced early-stage patent filings, pre-clinical developments, and conference poster and abstract submissions to identify promising new assets entering development.

BD&L Lead Assessment

Gather key CI data on the asset of interest and its competitive landscape to gauge investment viability and rapidly filter out nonviable leads.

Multiplying CI Efficiency

Automate the most time-intensive data search, aggregation, and curation components of CI research to 10x your team's output.

How Biotech VCs & Accelerators Use Our Intelligence

Investment Due Diligence

Low-noise, easily digestible, rapid-turnaround diligence data to assess investment opportunities at any stage of consideration.

Portfolio Asset Monitoring

Ongoing intelligence to detect meaningful changes in market opportunity, commercial viability, and the investment thesis for portfolio biotech companies.

Portfolio Operational Enablement

Pharma-grade CI capabilities delivered to small biotech portfolio companies, enabling them to stay lean, avoid additional FTEs, accelerate their pipelines, and grow their valuation.

How Private Equity Teams Use Our Intelligence

Pre-LOI Screening

Rapid clinical and competitive landscape overviews to qualify or disqualify targets before committing resources to full diligence.

Confirmatory Due Diligence

Deep-dive reports covering regulatory pathway risk, clinical differentiation, and commercial potential to support IC memos.

Portfolio Monitoring Briefs

Event-triggered briefs when something moves: a competitor's poster at ASCO, an FDA complete response letter, a pivotal readout. 1-5 page actionable summaries delivered within 48 hours, so your team is never caught off guard.

Value Creation Planning

Evidence-based commercial strategy inputs for portfolio companies, including market access analysis, payer landscape mapping, and pricing benchmarks.